197 p., [ES] El transportador ATP-Binding Cassette G2 (ABCG2) es una proteína integral de membrana
perteneciente a la subfamilia G de los transportadores ATP-Binding Cassette (ABC) que funciona
como una bomba de eflujo poliespecífica capaz de exportar un amplio espectro de sustancias de
diversa naturaleza molecular (compuestos endógenos, naturales, fármacos y otros xenobióticos)
hacia el exterior de las células (Eckenstaler y Benndorf, 2020). Esta proteína se expresa en la
membrana apical de las células de numerosos tejidos y órganos de interés farmacológico y
toxicológico implicados en la biodisponibilidad de sus sustratos tales como el intestino, el hígado o
el riñón, así como en las principales barreras fisiológicas (hematoencefálica, hematotesticular y
fetoplacentaria) (Vlaming et al., 2009; Stacy et al., 2013), regulando la entrada de sustancias no
deseadas, como ciertas toxinas, al interior del organismo. Además, es uno de los principales
responsables de la ampliamente conocida resistencia frente a múltiples fármacos (Duvivier et al.,
2024). En contraposición al papel protector previamente descrito, ABCG2 también participa en el
paso a leche de numerosas moléculas incluyendo algunos fármacos de uso veterinario, como los
antiparasitarios, los cuales representan el sector más importante de la industria farmacéutica animal
(Blanco-Paniagua et al., 2022a). Asimismo, participa en la secreción de algunas vitaminas, como la
riboflavina y el ácido fólico, y de compuestos estrogénicos, como los fitoestrógenos, a la leche (van
Herwaarden et al., 2007; García Mateos et al., 2017)., [EN] Considering that milk is a crucial food source for the optimal growth and development of
mammals, as well as a vital component of human diet worldwide, understanding any factor that could
affect the transport of xenobiotics (such as drugs) or natural substances (such as vitamins and
hormones) to milk is a priority. This knowledge is essential to predict and mitigate potential
unexpected contamination of dairy products and to produce safe, high-quality milk with improved
nutritional value.
In dairy animals, the use of antiparasitic agents is a widespread practice for treatment and
prevention of parasitic diseases (Lanusse et al., 2018). However, despite its undoubted benefits, the
potential risk of unwanted elimination of pharmacological residues in food products intended for
human consumption, such as milk, is a major concern for food safety and public health (Virkel et al.,
2018). Conversely, milk transfer of beneficial endogenous compounds naturally synthesized by the
animal, such as vitamins, could improve the nutritional quality of dairy products for consumers
(García-Lino et al., 2019).
In this context, and due to its relevant role in the secretion of its substrates into milk, as well
as its influence on their plasma and tissue profile, the study of the interaction of the ABCG2 transporter
with compounds present in milk both naturally and after exogenous administration is of particular
relevance. Interestingly, the physiological role of this protein in the mammary gland remains slightly
paradoxical. ABCG2 is known to facilitate the transfer of essential nutrients and vitamins, such as
folic acid and riboflavin, to newborn. However, it is also responsible for the secretion of toxic substances, including certain drugs, into milk, which could pose risks to both breast-fed infants and
consumers of dairy products (Imperiale & Lanusse, 2021). Given this dual role, the primary goal of
our research group is to understand why a protein that apparently protects the body from xenobiotic
exposure can also facilitate the accumulation of toxic substrates in milk, a function that seems difficult
to reconcile with the need to protect the offspring.
Considering the aforementioned, this PhD Thesis aimed to explore the involvement of ABCG2
in the in vitro transport, plasma and tissue bioavailability, and milk secretion of the endogenous
compound melatonin, and the antiparasitic drugs thiabendazole and nitroxynil. To achieve this goal,
a common methodology was employed. First, in vitro transepithelial transport assays were conducted
using Madin-Darby Canine Kidney II (MDCK-II) cells and its subclones transduced with the murine,
ovine, bovine, and human isoforms of the ABCG2 transporter to evaluate its role in the active transport
of these molecules. Second, in vivo studies were performed using male wild-type and Abcg2(–/–) mice
to assess the effect of this transporter on plasma bioavailability and tissue distribution of these
compounds. Third, lactating mice were used to examine whether the Abcg2 transporter influences
their milk secretion. Finally, metabolomic analyses were carried out to determine the impact of ABCG2
on milk metabolome.